BioNTech SE (0A3M.IL)
| Previous close | 91.38 |
| Open | 96.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 88.30 - 96.00 |
| 52-week range | 85.38 - 125.74 |
| Volume | |
| Avg. volume | 3,839 |
| Market cap | 24.288B |
| Beta (5Y monthly) | 0.24 |
| PE ratio (TTM) | 4.91 |
| EPS (TTM) | 18.00 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 06 Jun 2022 |
| 1y target est | 219.54 |
- Reuters
UPDATE 1-BioNTech says 90% of 2024 revenues will accrue at end of year
Germany's BioNTech , whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.
ReutersBioNTech says 90% of 2024 revenues will accrue at end of year
FRANKFURT (Reuters) -Germany's BioNTech, whose COVID-19 vaccine in partnership with Pfizer was widely used during the pandemic, said on Monday that almost all of its expected 2024 revenues would come in at the end of the year. BioNTech, which is investing money earned during the pandemic in cancer drug development, said in a statement that it is still targeting 2024 revenues in a range of 2.5 billion euros ($2.69 billion) to 3.1 billion euros. "BioNTech expects to recognize approximately 90% of its full year revenues in the last months of 2024," the company added.
Globe NewswireBioNTech Announces First Quarter 2024 Financial Results and Corporate Update
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low chemotherapy-naïve metastatic breast cancer patients, and a second Phase 3 trial with BNT323/DB-1303 in recurrent endometrial cancer planned to start soonPresented clinical data at the American Association for Cancer Research (“AACR”) Annual Meeting for individualized and off-the-shelf mRNA-based cancer vaccine
